EL7.AI
Stocks•16 July 2026•
1 min read

DBV Technologies Bolsters Cash Runway, Eyes 2026 BLA Submission for Peanut Patch

Key Facts

1DBV Technologies reported Q2 and H1 2026 financial results with cash and cash equivalents of $174.9 million as of June 30, 2026.
2DBV Technologies anticipates submitting the BLA for the Viaskin Peanut Patch in children aged 4-7 in Q3 2026.
3PDF Solutions announced it will release its second quarter fiscal 2026 financial results on August 6, 2026.

Amid growing investor focus on biotech advancements in food allergy treatments, DBV Technologies reported its Q2 and H1 2026 financial results, highlighting a cash position of $174.9 million as of June 30, 2026. According to reports, the company anticipates submitting the Biologics License Application (BLA) for its Viaskin Peanut patch for children aged 4-7 in the third quarter of 2026. Separately, PDF Solutions has scheduled its second-quarter earnings release for August 6, 2026.

DBV's current liquidity provides a stable runway compared to biotech peers; for context, competitors like Aimmune Therapeutics saw significant market movement following the approval of Palforzia, placing pressure on DBV to meet its regulatory milestones. Compared to previous quarters, the company maintains an expenditure rate that supports operations into 2027, a trend consistent with late-stage clinical firms per market data.

Looking ahead, traders are eyeing the PDF Solutions earnings call on August 6 as a key catalyst for the semiconductor software sector. For DBV, the primary focus remains on any interim FDA feedback regarding the Viaskin trials.